US · ATXS
Astria Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Boston, MA 02110
- Website
- astriatx.com
Price · as of 2024-12-31
—
Market cap 712.21M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $385.20 | ||||
| 2016 | $122.40 | ||||
| 2017 | $123.00 | ||||
| 2018 | $32.46 | $52.30 | |||
| 2019 | $29.46 | ||||
| 2020 | $20.22 | ||||
| 2021 | $6.73 | ||||
| 2022 | $11.67 | ||||
| 2023 | $14.35 | ||||
| 2024 | $6.19 |
AI valuation
Our deep-learning model estimates Astria Therapeutics, Inc.'s (ATXS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ATXS | Astria Therapeutics, Inc. | $12.62 | 712.21M | — | — | — | — | -3.69 | 1.09 | — | -0.26 | — | 1.09 | 0.00% | — | — | -33.52% | 3380.03% | -31.58% | 0.02 | — | 17.49 | 17.15 | 0.58 | -3058.00% | — | 1908.00% | -23.45% | -4.25 | 2470.44% | 0.00% | 0.00% | 0.00% | -0.22 | -0.30 | — | 6.30 |
| ARVN | Arvinas, Inc. | $9.57 | 702.61M | +152% | -16% | -95% | — | -10.76 | 2.00 | 3.31 | -2.55 | — | 2.00 | 98.02% | -43.75% | -30.77% | -16.23% | 32.32% | -8.93% | 0.02 | — | 4.92 | 4.88 | 1.78 | -5379.00% | -30.00% | 559.00% | -31.73% | -1.92 | 77.55% | 0.00% | 0.00% | 15.59% | -1.67 | -0.70 | 0.73 | -0.54 |
| AVBP | ArriVent BioPharma, Inc. … | $18.33 | 743.63M | — | — | — | — | -8.55 | 2.67 | — | -5.83 | -47.58 | 2.67 | 0.00% | — | — | -39.36% | -469.29% | -36.75% | 0.00 | — | 13.14 | 12.70 | 0.92 | 1797.00% | — | 2573.00% | -10.20% | -4.06 | -349.38% | 0.00% | 0.00% | 0.00% | -4.98 | -6.69 | — | 22.46 |
| DAWN | Day One Biopharmaceutical… | $9.14 | 936.23M | +208% | +61,299% | — | — | -9.99 | 2.43 | 6.78 | -5.99 | -509.45 | 2.53 | 89.12% | -80.76% | -67.85% | -22.74% | 1066.44% | -19.68% | 0.01 | — | 8.02 | 7.73 | 1.84 | 196.00% | 2060.00% | 2964.00% | -9.71% | -1.71 | 884.82% | 0.00% | 0.00% | 6.71% | -4.96 | -6.09 | 4.01 | 8.31 |
| DNA | Ginkgo Bioworks Holdings,… | $11.59 | 642.42M | +2% | -71% | — | +668% | -1.25 | 0.77 | 2.30 | -1.51 | — | 0.87 | 81.48% | -185.29% | -183.81% | -51.08% | -55.89% | -25.05% | 0.82 | — | 4.92 | 4.65 | -0.98 | -4649.00% | -2506.00% | -5323.00% | -45.71% | -1.78 | -31.77% | 0.00% | 0.00% | 0.00% | -1.22 | -2.16 | 2.27 | -7.68 |
| ERAS | Erasca, Inc. | $2.20 | 624.07M | — | — | — | — | -2.21 | 0.84 | — | -0.73 | — | 0.84 | 0.00% | — | — | -43.68% | -151.38% | -36.01% | 0.12 | — | 9.84 | 9.58 | 0.10 | -1687.00% | — | 2814.00% | -36.89% | -3.49 | -111.24% | 0.00% | 0.00% | 0.00% | -0.62 | -0.84 | — | 0.06 |
| IOVA | Iovance Biotherapeutics, … | $1.81 | 654.96M | +1,533% | -16% | — | — | -3.46 | 1.94 | 5.14 | -3.10 | — | 3.23 | 97.23% | -153.08% | -148.38% | -55.50% | -89.67% | -42.88% | 0.07 | — | 3.20 | 2.74 | 0.32 | -1484.00% | 6060.00% | -764.00% | -24.83% | -2.19 | -75.14% | 0.00% | 0.00% | 4.22% | -2.74 | -3.29 | 4.20 | -1.24 |
| MBX | MBX Biosciences, Inc. Com… | $22.55 | 757.53M | — | — | — | — | -5.33 | 1.28 | — | -1.00 | -6.55 | 1.28 | 0.00% | — | — | -66.95% | 86.67% | -35.11% | 0.00 | — | 24.19 | 23.78 | 0.72 | 8137.00% | — | 7303.00% | -16.82% | -4.95 | 70.61% | 0.00% | 0.00% | 5.75% | -1.00 | -1.23 | — | 17.45 |
| MGTX | MeiraGTx Holdings plc | $8.58 | 689.96M | +305% | -70% | — | — | -3.01 | 6.57 | 13.39 | -3.51 | -7.13 | 6.65 | 28.51% | -493.44% | -444.10% | -143.48% | -223.66% | -49.55% | 1.25 | -12.37 | 2.03 | 1.88 | 0.15 | 4228.00% | 13742.00% | -1282.00% | -24.57% | -1.72 | -149.07% | 0.00% | 0.00% | 0.00% | -2.60 | -3.90 | 12.82 | -3.93 |
| REPL | Replimune Group, Inc. | $8.58 | 669.72M | — | — | — | — | -3.38 | 2.01 | — | -1.69 | — | 2.01 | 0.00% | — | — | -62.58% | -1380.14% | -47.60% | 0.18 | -33.15 | 7.95 | 7.82 | 0.14 | -525.00% | — | 409.00% | -23.79% | -3.08 | -1049.44% | 0.00% | 0.00% | 4.35% | -1.64 | -2.15 | — | 0.67 |
| VALN | Valneva SE | $9.00 | 710.19M | +288% | -59% | -78% | — | -34.66 | 2.34 | 2.50 | 14.73 | — | 2.72 | 41.89% | 7.86% | -7.22% | -7.91% | 6.06% | -2.55% | 1.19 | 0.56 | 2.61 | 1.78 | 1.50 | -8836.00% | 1032.00% | -6146.00% | -19.71% | -0.59 | -38.00% | 0.00% | 0.00% | 8.17% | 35.45 | -5.65 | 2.79 | 0.09 |
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
- CEO
- Jill C. Milne
- Employees
- 78
- Beta
- 0.07
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).